Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 16/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16330568 | 0.87 | HDAC3 (0.40) | CA14KIF11L3MBTL1HDAC3HDAC1 | |
| SCHEMBL12917528 | 0.86 | KIF11 (0.46) | KIF11 | |
| SCHEMBL17493268 | 0.83 | KIF11 (0.43) | KIF11HDAC3HDAC1HDAC2 | |
| SCHEMBL18291881 | 0.81 | CA14 (0.41) | CA14KIF11L3MBTL1HDAC3HDAC1 | |
| SCHEMBL26616743 | 0.81 | ACHE (0.43) | KIF11 | |
| SCHEMBL14708941 | 0.80 | CA14 (0.45) | CA14KIF11L3MBTL1HDAC3HDAC1 | |
| SCHEMBL16141285 | 0.80 | CA14 (0.45) | CA14KIF11L3MBTL1HDAC3HDAC1 | |
| SCHEMBL26995518 | 0.80 | L3MBTL1 (0.48) | CA14L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL7983626 | 0.80 | L3MBTL1 (0.48) | CA14L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL12917526 | 0.79 | CA14 (0.39) | CA14KIF11L3MBTL1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342870-B2 | Nanoparticles for drug delivery | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20170224839-A1 | NANOPARTICLES FOR DRUG DELIVERY | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| WO-2016022845-A1 | NANOPARTICLES FOR DRUG DELIVERY | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224839-A1 | NANOPARTICLES FOR DRUG DELIVERY | MSN, CD47, MTHFD1 | CA14 241/4885KIF11 167/4885L3MBTL1 3305/4885 |
| US-10342870-B2 | Nanoparticles for drug delivery | MSN, CD47, MTHFD1 | CA14 241/4885KIF11 167/4885L3MBTL1 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.